Biotech Values

[jbog]

ronpopeil,

Never. Only remember such gains on the 1990s Internet stocks

Ironically, Merrill came out yesterday and said that Intercept is sitting on a new class of drugs and gave it a $872 price target.

To think it IPO'd at $15 fourteen months ago.


Intercept price target raised to $400 from $60 at Citigroup
Citigroup raised its price target for Intercept shares to $400 from $60 saying it still sees value in the stock despite yesterday's 300% gain. Citi believes the company's $5.4B market capitalization does not reflect its multi-billion dollar opportunity in non-alcoholic steatohepatitis/ liver fibrosis. The firm thinks Intercept's obeticholic acid could top $5B a year in sales and keeps a Buy rating on the stock.

ICPT Intercept price target raised to $872 from $81 at BofA/Merrill

BofA/Merrill raised Intercept's price target to $872 based on the potential OCA in nonalcoholic steatohepatitis, or NASH. The firm forecasts peak sales of $4B given the extraordinary study results. Shares are Buy rated.